Surrozen (NASDAQ:SRZN – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($11.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($9.92), FiscalAI reports.
Surrozen Stock Up 3.2%
Shares of Surrozen stock traded up $1.00 during trading on Monday, reaching $32.00. The company’s stock had a trading volume of 120,850 shares, compared to its average volume of 258,997. The business has a 50 day moving average price of $24.94 and a 200-day moving average price of $25.24. Surrozen has a 12-month low of $11.66 and a 12-month high of $37.83. The company has a market capitalization of $371.52 million, a P/E ratio of -0.79 and a beta of 0.51.
Wall Street Analyst Weigh In
A number of research firms have weighed in on SRZN. HC Wainwright reiterated a “buy” rating and issued a $54.00 target price (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. William Blair began coverage on Surrozen in a report on Thursday, August 20th. They set an “outperform” rating and a $51.00 price target for the company. Zacks Research upgraded shares of Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.33.
Read Our Latest Stock Analysis on SRZN
About Surrozen
Surrozen, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.
The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.
Read More
- Five stocks we like better than Surrozen
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
